Price
No data yet.
Social Signal Score
Company Profile
- Sector
- Financial Services
- Industry
- Asset Management - Bonds
- Beta
- 0.66
- Country
- US
Quote
Valuation & Ratios
Returns & Efficiency
Valuation
IBDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
95-5.00%Social Signal Score
Mentions (7)
- Newsprnewswire.com·36d ago·Neutral
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026 20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programs Latest long-term and real-world data with SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) provide additional insight into clinical and endoscopic outcomes over approximately three years in moderately to seve…
View source ↗ - Newszacks.com·39d ago·Positive
Is Inspire Corporate Bond ETF (IBD) a Strong ETF Right Now? Launched on 07/10/2017, the Inspire Corporate Bond ETF (IBD) is a smart beta exchange traded fund offering broad exposure to the Investment Grade Corporate Bond ETFs category of the market.
View source ↗ - Newsseekingalpha.com·46d ago·Positive
Spyre: Maintain 'Strong Buy' On Additional SPY072 Shots On Goal Q4 2026 And IBD Combination Potential Spyre Therapeutics maintains a 'Strong Buy' rating, driven by promising IBD pipeline progress and robust cash reserves. SYRE's three monotherapy candidates—SPY001, SPY002, SPY003—show potential best-in-class efficacy for IBD, with combination data expected in 2027. Despite discontinuing SPY072 monotherapy for RA, SYRE retains upside via upcoming PsA, axSpA, and combination readouts in late 2026–…
View source ↗ - Newsinvestors.com·62d ago·Positive
AI-Fueled Precision Oncology Firm Guardant Health Is In Focus. Here's Why. Earning a spot on the IBD Leaderboard and IBD 50, Guardant Health stress tests a breakout.
View source ↗ - Newsprnewswire.com·89d ago·Neutral
Inspire Corporate Bond Fund (IBD) Receives 5-star Overall Morningstar Rating™ Among 155 Corporate Bond Funds BOISE, Idaho, Aug. 25, 2026 /PRNewswire/ -- Inspire Investing is pleased to announce that the Inspire Corporate Bond ETF (NYSE: IBD) has been awarded a 5-star Overall Morningstar Rating™ for the 5-year period out of 155 Corporate Bond funds as of 7/31/26. Morningstar's rating system evaluates funds based on their risk-adjusted returns relative to category peers, with the top 10% of funds …
View source ↗ - Newszacks.com·90d ago·Positive
Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD? SYRE expands into HS with SPY772, testing whether dual-pathway inhibition can strengthen outcomes in SKYLIGHT.
View source ↗ - Newszacks.com·104d ago·Positive
Is Inspire Corporate Bond ETF (IBD) a Strong ETF Right Now? Launched on 07/10/2017, the Inspire Corporate Bond ETF (IBD) is a smart beta exchange traded fund offering broad exposure to the Investment Grade Corporate Bond ETFs category of the market.
View source ↗
Congress trades
No disclosed congressional trades in IBD.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
